4 active not recruiting, 1 available, 1 completed, 1 enrolling by invitation. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Active not recruiting 2, Enrolling by invitation 1, Recruiting 1 |
Follow USWM CT, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPEARHEAD-3 Pediatric Study Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 / Phase 2 | Recruiting | USWM CT, LLC | 20 | 2023-09-01 | 2026-08-11 |
| ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab - Ovarian Cancer | Phase 2 | Terminated | USWM CT, LLC | 21 | 2023-06-26 | 2026-10-19 |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide - Neoplasms | Phase 2 | Active not recruiting | USWM CT, LLC | 103 | 2019-12-31 | 2026-08-11 |
| Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine - Neoplasms | Phase 2 | Completed | USWM CT, LLC | 82 | 2019-12-31 | 2026-08-13 |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks - Endometrial Cancer, Esophageal Cancer | Phase 1 | Active not recruiting | USWM CT, LLC | 120 | 2019-08-20 | 2026-09-23 |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma afamitresgene autoleucel (previously ADP-A2M4) - Synovial Sarcoma, Myxoid Liposarcoma | Phase 2 | Active not recruiting | USWM CT, LLC | 52 | 2019-08-13 | 2026-08-26 |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study ADP adoptive cell therapy - Neoplasms | Phase 1 | Enrolling by invitation | USWM CT, LLC | 250 | 2018-04-09 | 2026-08-11 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation - Urinary Bladder Cancer, Melanoma | Phase 1 | Active not recruiting | USWM CT, LLC | 71 | 2017-05-15 | 2026-06-04 |
| Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel Non-conforming afamitresgene autoleucel - Synovial Sarcoma, Myxoid Liposarcoma | Available | USWM CT, LLC | 2026-08-11 |
Sarcoma, Synovial (5) · Liposarcoma, Myxoid (4) · Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Endometrial Neoplasms (1) · Neuroblastoma (1) · Neurofibrosarcoma (1)
Cyclophosphamide (2) · fludarabine (2) · Nivolumab (1) · Radiation (1)
United States (9) · Canada (7) · Spain (6) · United Kingdom (5) · France (4) · Italy (3) · Netherlands (3) · Australia (1) · Germany (1)
David Hong, MD (2) · Michael Nathenson, MD (2) · Dejka Araujo, MD (1) · Fiorella Iglesias Cardenas, MD (1)